Last Updated: November 22, 2026

rexulti Drug Patent Profile

« Back to Dashboard


When do Rexulti patents expire, and what generic alternatives are available?

Rexulti is a drug marketed by Otsuka and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in REXULTI is brexpiprazole. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the brexpiprazole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rexulti

A generic version of rexulti was approved as brexpiprazole by ALEMBIC on January 13th, 2025.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for rexulti?
  • What are the global sales for rexulti?
  • What is Average Wholesale Price for rexulti?
Recent Clinical Trials for rexulti

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dalhousie UniversityPhase 4
University of MichiganPhase 4
Unity Health TorontoPhase 4

See all rexulti clinical trials

Pharmacology for rexulti
Paragraph IV (Patent) Challenges for REXULTI
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
REXULTI Tablets brexpiprazole 4 mg 205422 16 2019-07-10

US Patents and Regulatory Information for rexulti

rexulti is protected by five US patents and five FDA Regulatory Exclusivities.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 AB RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Otsuka REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Otsuka REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 AB RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Otsuka REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 AB RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Otsuka REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 AB RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Otsuka REXULTI brexpiprazole TABLET;ORAL 205422-006 Jul 10, 2015 AB RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for rexulti

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V. Rxulti brexpiprazole EMEA/H/C/003841Treatment of schizophrenia. Authorised no no no 2018-07-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for rexulti

When does loss-of-exclusivity occur for rexulti?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 8319
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 12321723
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2014008603
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 51588
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 14000909
Estimated Expiration: ⤷  Start Trial

China

Patent: 3889425
Estimated Expiration: ⤷  Start Trial

Patent: 7397730
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 50480
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0200037
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 22460
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 67285
Estimated Expiration: ⤷  Start Trial

Eurasian Patent Organization

Patent: 2930
Estimated Expiration: ⤷  Start Trial

Patent: 1490783
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 67285
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 67285
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 47493
Estimated Expiration: ⤷  Start Trial

India

Patent: 55DEN2014
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 1513
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 84161
Estimated Expiration: ⤷  Start Trial

Patent: 17088610
Estimated Expiration: ⤷  Start Trial

Patent: 2013054872
Estimated Expiration: ⤷  Start Trial

Jordan

Patent: 53
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 67285
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 3370
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 6092
Estimated Expiration: ⤷  Start Trial

Patent: 14004135
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 2639
Estimated Expiration: ⤷  Start Trial

Philippines

Patent: 014500607
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 67285
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 67285
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 201608412S
Estimated Expiration: ⤷  Start Trial

Patent: 14013783
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 67285
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1402333
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 2072371
Estimated Expiration: ⤷  Start Trial

Patent: 140075754
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 62479
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 1318651
Estimated Expiration: ⤷  Start Trial

Patent: 34908
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 4411
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering rexulti around the world.

Country Patent Number Title Estimated Expiration
Argentina 088319 ⤷  Start Trial
Australia 2012321723 ⤷  Start Trial
Brazil 112014008603 ⤷  Start Trial
Canada 2851588 ⤷  Start Trial
Chile 2014000909 ⤷  Start Trial
China 103889425 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for rexulti

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1869025 300946 Netherlands ⤷  Start Trial PRODUCT NAME: BREXPIPRAZOLE, DESGEWENST IN DE VORM VAN EEN ZOUT; REGISTRATION NO/DATE: EU/1/18/1294 20180727
1869025 122018000088 Germany ⤷  Start Trial PRODUCT NAME: BREXPIPRAZOL ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1294 20180726
1869025 PA2018509 Lithuania ⤷  Start Trial PRODUCT NAME: BREKSPIPRAZOLAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/18/1294 20180726
1869025 CA 2018 00028 Denmark ⤷  Start Trial PRODUCT NAME: BREXPIPRAZOL ELLER ET SALT DERAF; REG. NO/DATE: EU/1/18/1294/001-006 20180727
1869025 LUC00086 Luxembourg ⤷  Start Trial PRODUCT NAME: BREXPIPRAZOLE OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1294 20180730
1869025 32/2018 Austria ⤷  Start Trial PRODUCT NAME: BREXPIPRAZOL ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1294 (MITTEILUNG) 20180727
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

REXULTI Market Dynamics, Financial Trajectory, Patent Exclusivity, and Generic Risk

Last updated: November 4, 2026

REXULTI, the brand name for brexpiprazole, has developed from an atypical antipsychotic for schizophrenia and adjunctive major depressive disorder into a broader neuropsychiatric franchise. Its 2023 FDA approval for agitation associated with Alzheimer’s dementia materially expanded the addressable market. U.S. sales growth remains supported by the Alzheimer’s indication, while long-term valuation depends on patent durability, generic litigation, payer management, and the ability of Otsuka and Lundbeck to defend premium pricing.

As of the end of 2024, REXULTI remained a commercially significant product with no publicly established generic launch in the United States. It is a small-molecule product, so its principal post-exclusivity threat is abbreviated new drug application, or ANDA, competition rather than biosimilar substitution.

What is REXULTI and who commercializes brexpiprazole?

REXULTI is brexpiprazole, an oral dopamine D2 and serotonin 5-HT1A partial agonist with serotonin 5-HT2A antagonist activity. Otsuka Pharmaceutical and H. Lundbeck A/S developed the product under a global collaboration.

Item Detail
Active ingredient Brexpiprazole
Brand REXULTI
Drug class Atypical antipsychotic
Dosage form Oral tablets
U.S. sponsors Otsuka Pharmaceutical and Lundbeck
Initial FDA approval July 2015
Initial indications Schizophrenia; adjunctive treatment of major depressive disorder
Expanded indication Agitation associated with Alzheimer’s dementia, approved May 2023
Regulatory pathway New drug application
Generic pathway ANDA, not biosimilar
Primary commercial markets United States, Japan, Europe, and selected international markets

The Alzheimer’s agitation indication was the principal strategic expansion. The FDA approval was based on two positive placebo-controlled studies in patients with probable Alzheimer’s dementia experiencing agitation. The label includes a boxed warning concerning increased mortality in elderly patients with dementia-related psychosis and a cerebrovascular adverse-event warning. REXULTI is not approved for dementia-related psychosis itself. [1]

How has REXULTI revenue changed over time?

REXULTI has moved from launch-stage antipsychotic to a multibillion-yen and multibillion-kroner global product. Reported figures vary because Otsuka and Lundbeck record revenue by geography and accounting arrangement rather than publishing one fully consolidated REXULTI number.

Period Commercial development Financial interpretation
2015-2017 U.S. launch in schizophrenia and adjunctive MDD Market adoption depended on differentiation from aripiprazole and other generic antipsychotics
2018-2020 Expansion in depression augmentation and international markets Higher prescription volume offset intense competition in the broader antipsychotic category
2021-2022 Continued U.S. growth Product became an important Lundbeck growth contributor
2023 FDA approval for Alzheimer’s agitation New indication created a second major growth vector
2024 Wider commercial rollout of Alzheimer’s indication Revenue growth remained positive, but payer controls and safety warnings constrained penetration

Lundbeck has reported REXULTI revenue in the approximate range of DKK 3.8 billion for 2023 and DKK 4.4 billion for 2024, based on its annual-report product disclosures. Otsuka reports its share through its pharmaceutical segment and Japanese accounting disclosures. The two figures should not be added mechanically because each company reports different geographic and contractual portions of the product’s economics. [2][3]

The product’s combined global sales are generally understood to be above US$1 billion annually, with the United States representing the dominant market. The Alzheimer’s agitation label provides the main source of incremental growth because the schizophrenia and MDD markets are more mature and exposed to generic alternatives in competing therapies.

What drives REXULTI market growth?

Four factors determine the product’s commercial trajectory.

Alzheimer’s agitation expands the treated population

Agitation is common in Alzheimer’s dementia and has limited FDA-approved pharmacologic treatment options. The 2023 approval allows physicians to prescribe REXULTI for a defined symptom domain rather than relying solely on off-label antipsychotic use.

The opportunity is large, but the eligible commercial population is narrower than the overall Alzheimer’s population. Treatment is generally directed at patients with clinically significant agitation after nonpharmacologic interventions and risk assessment. The boxed warning limits use and affects prescriber behavior.

REXULTI benefits from a differentiated commercial position

In depression, REXULTI competes with generic antidepressants and other adjunctive agents, including generic aripiprazole. Its commercial value depends on tolerability, physician familiarity, formulary access, and persistence.

Compared with aripiprazole, brexpiprazole is generally positioned as having lower akathisia risk in some clinical settings, although comparative treatment decisions remain patient-specific. That positioning supports premium pricing but does not eliminate payer pressure.

The product has multiple indications

A multi-indication label reduces dependence on one specialty market. Schizophrenia supports psychiatry demand, MDD supports primary-care and psychiatric augmentation, and Alzheimer’s agitation adds neurology, geriatrics, and memory-care demand.

The same breadth also creates regulatory and commercial constraints. The dementia indication carries heightened safety scrutiny, and broad antipsychotic class warnings limit promotional flexibility.

Commercial infrastructure supports durable prescribing

Otsuka and Lundbeck have established relationships with psychiatric prescribers, hospitals, specialty pharmacies, and managed-care organizations. The companies can use the existing REXULTI infrastructure to support the Alzheimer’s launch without building an entirely new commercial platform.

What is the FDA regulatory status of REXULTI?

REXULTI is fully approved in the United States for three principal uses:

  1. Treatment of schizophrenia in adults.
  2. Adjunctive treatment of major depressive disorder in adults.
  3. Treatment of agitation associated with dementia due to Alzheimer’s disease.

The Alzheimer’s approval is commercially important but carries the most substantial regulatory risk. The FDA label states that elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. REXULTI is not approved for dementia-related psychosis, and the label prohibits treating that broader condition under the Alzheimer’s agitation approval. [1]

The product is not a biologic. Biosimilar substitution is therefore not relevant. The relevant future competition is generic brexpiprazole under the ANDA pathway.

What patents protect REXULTI?

REXULTI’s U.S. patent estate has included composition-of-matter, chemical-structure, formulation, and method-of-use protection. Public patent records associate key brexpiprazole protection with Otsuka and related entities.

Protection category Representative U.S. patent Commercial relevance
Core brexpiprazole compound and chemical class U.S. Patent No. 7,888,362 Principal early composition protection
Additional compound or therapeutic claims U.S. Patent No. 8,338,486 Supports protection beyond the earliest compound patent
Solid-state, formulation, or therapeutic-use claims Later Otsuka patents and Orange Book-listed continuations Can delay or complicate generic approval
Alzheimer’s agitation use Later method-of-use protection associated with the expanded indication Protects the approved use, not necessarily all brexpiprazole sales

The earliest core patent protection is generally associated with expiration in the 2026-2027 period, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the exact claims asserted. Later patents can extend protection for specific formulations or approved uses into the late 2020s or beyond, but they do not necessarily block a generic from entering for every indication.

The FDA Orange Book is the controlling source for current listed patents, pediatric exclusivity, and the expiration information used in ANDA certification analysis. Patent listings can change as sponsors add, delist, or correct patents. [4]

When does REXULTI lose exclusivity?

REXULTI’s effective loss-of-exclusivity date depends on three separate events:

Exclusivity layer Expected timing Impact
Core compound patent protection Approximately 2026-2027 Highest risk of broad generic entry
Later formulation and method patents Approximately 2028-2035, depending on patent and claim May preserve selected uses or delay launches
FDA regulatory exclusivity for Alzheimer’s agitation Limited period associated with the 2023 approval Does not independently create long-term market protection

The core risk is a generic applicant that certifies Paragraph IV against listed patents and wins, settles, or otherwise resolves the resulting litigation. Later method-of-use patents may allow a skinny-label generic that excludes the Alzheimer’s indication while entering for schizophrenia and MDD.

A patent expiry date does not automatically equal a full-market generic launch date. Commercial entry may be delayed by litigation, settlement terms, manufacturing readiness, FDA approval timing, controlled-distribution requirements, or the economic value of launching at risk.

Which companies are challenging REXULTI patents?

Publicly identified ANDA challengers and litigation details have not produced a single confirmed generic launch date for brexpiprazole through the end of 2024. Generic companies commonly involved in large CNS-product challenges include Teva, Lupin, Zydus, Alembic, Hetero, and related applicants, but the identity of a challenger must be tied to a specific court docket or FDA Paragraph IV notice before it is treated as confirmed.

A Paragraph IV certification means that an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. The sponsor may file a patent-infringement action within 45 days, triggering a statutory stay of FDA approval that can last up to 30 months, subject to court action and statutory exceptions. [5]

The most consequential litigation question is whether challengers attack the core compound claims or only later formulation and method-of-use patents. A successful challenge to the core compound claims would create broad entry risk. A successful challenge limited to a use patent could leave branded REXULTI sales intact in protected indications while permitting a generic for nonprotected uses.

What formulation and method-of-use patents protect REXULTI?

Formulation patents can cover dosage strengths, solid forms, particle characteristics, excipients, dissolution profiles, or manufacturing processes. Method-of-use patents can cover treatment of specific disorders or patient populations.

For REXULTI, the most commercially important later-use protection is associated with agitation in Alzheimer’s dementia. Its value depends on whether a generic product can enter with a label that omits the protected indication and whether pharmacists, payers, and prescribers keep the generic effectively confined to nonprotected uses.

Formulation patents are usually weaker than valid composition patents because their enforceability depends on claim scope, prosecution history, obviousness, and the ability of a generic manufacturer to design around the claims. They can still delay entry when combined with a statutory stay or settlement restriction.

What generic launch scenarios exist for REXULTI?

Scenario 1: Broad launch after core patent loss

A generic enters for all or most REXULTI strengths after defeating or resolving core patents. Price erosion could be substantial, particularly in schizophrenia and MDD, where physicians are accustomed to generic antipsychotic treatment.

Scenario 2: Skinny-label launch

A generic launches for schizophrenia and MDD but excludes Alzheimer’s agitation. This would preserve some branded dementia revenue while exposing the mature indications to rapid substitution.

Scenario 3: Negotiated delayed entry

Otsuka, Lundbeck, and generic applicants settle litigation with a defined entry date. The settlement could include limited use rights, patent-license terms, or restrictions associated with particular patents. Public assessment must rely on filed agreements and FTC review where applicable. [6]

Scenario 4: Litigation-driven delay

The branded companies prevail on one or more patents, or a court maintains a stay through the relevant approval period. This scenario extends exclusivity but increases litigation expense and does not eliminate later entry risk.

How strong is the REXULTI patent estate?

The estate is commercially meaningful but not uniformly strong.

Factor Assessment
Core compound protection Strongest protection, but earliest expiration creates a defined cliff
Multiple indications Positive for lifecycle management and revenue retention
Alzheimer’s method patenting Potentially valuable, but vulnerable to skinny-label strategies
Formulation patents Moderate value; subject to design-around and validity challenges
Patent-term timing Critical because later patents may not block all indications
Regulatory exclusivity Helpful for launch support but not a substitute for durable patent protection
Litigation exposure Material through the first broad generic challenge

The strongest defense is the combination of high prescription volume, multiple indications, later-use claims, and commercial execution. The principal weakness is that the molecule is a small-molecule oral tablet with a foreseeable generic pathway. Once broad generic brexpiprazole becomes available, brand retention will depend on clinical preference, payer contracts, patient stability, and rebate economics.

How does REXULTI compare with competing antipsychotics?

Product Active ingredient Generic status Key commercial difference
REXULTI Brexpiprazole Branded through the relevant exclusivity period MDD augmentation and Alzheimer’s agitation indications
ABILIFY Aripiprazole Generic available Broad clinical history and low-cost competition
VRAYLAR Cariprazine Branded Competes in schizophrenia, bipolar disorder, and MDD
LATUDA Lurasidone Generic available Strong historical bipolar and schizophrenia presence
CAPLYTA Lumateperone Branded Competes in schizophrenia, bipolar depression, and MDD
SEROQUEL XR Quetiapine extended release Generic competition Established use but heavy price pressure

REXULTI’s competitive advantage is the combination of adjunctive MDD adoption and the FDA-approved Alzheimer’s agitation indication. Its main disadvantage is premium pricing against generic aripiprazole and other low-cost alternatives.

What revenue exposure exists after generic entry?

The Alzheimer’s indication is likely to be the most valuable protection for the late-life revenue curve, assuming the branded companies maintain effective indication-specific promotion and payer differentiation. Schizophrenia and MDD sales are more exposed to broad generic substitution once core patents expire.

A likely revenue pattern is:

  1. Continued growth during Alzheimer’s indication expansion.
  2. Slower growth as formulary restrictions and safety concerns moderate uptake.
  3. Initial erosion after broad generic approval.
  4. Faster decline in mature indications than in protected or clinically differentiated use.
  5. Residual branded revenue from dementia care, stable patients, and prescribers who prefer the branded product.

The scale of erosion will depend on the number of first-wave entrants. One or two generic entrants can preserve meaningful prices temporarily. A crowded generic field usually produces much faster price compression.

What licensing deals support REXULTI?

Otsuka and Lundbeck operate under a long-standing collaboration covering development and commercialization of brexpiprazole. The agreement gives Lundbeck substantial commercial participation outside Japan and reflects the partners’ shared development history.

The agreement is strategically important because it aligns global commercialization, regulatory submissions, and lifecycle management. It also means revenue and profit exposure is divided between the companies rather than reported by a single manufacturer. Public annual reports provide product and segment revenue, but they do not always disclose the complete product-level economics of every territory. [2][3]

Key Takeaways

  • REXULTI is brexpiprazole, a small-molecule atypical antipsychotic marketed by Otsuka and Lundbeck.
  • The 2023 Alzheimer’s agitation approval created the product’s principal new growth opportunity.
  • Global REXULTI revenue is above the billion-dollar scale, with Lundbeck reporting approximately DKK 3.8 billion in 2023 and DKK 4.4 billion in 2024.
  • Core patent protection is generally associated with the 2026-2027 period, while later formulation and method patents may extend selected protection into the late 2020s or beyond.
  • Generic risk is based on ANDA Paragraph IV litigation, not biosimilar competition.
  • A skinny-label generic could enter schizophrenia and MDD while leaving Alzheimer’s agitation subject to separate method-of-use protection.
  • The patent estate is commercially useful but cannot guarantee protection against broad generic entry after core compound expiry.
  • Revenue exposure is highest in mature schizophrenia and MDD uses and potentially lower in the newer Alzheimer’s agitation market.

FAQs About REXULTI Patent Expiration and Market Competition

Is REXULTI a biologic or a small-molecule drug?

REXULTI is a small-molecule drug. Generic manufacturers can seek approval through the ANDA pathway. Biosimilar regulation does not apply.

Does REXULTI have an Alzheimer’s disease approval?

REXULTI is approved for agitation associated with dementia due to Alzheimer’s disease. It is not approved to treat Alzheimer’s dementia itself or dementia-related psychosis generally.

Can generic brexpiprazole launch before every REXULTI patent expires?

Potentially. An ANDA applicant may certify that a patent is invalid, unenforceable, or not infringed. A court decision, settlement, or skinny-label strategy can permit entry before every listed patent expires.

Why is the Alzheimer’s indication important to REXULTI valuation?

It expands the product into a large patient population with limited approved pharmacologic options. It also supports lifecycle management after the schizophrenia and MDD markets mature.

What is the main financial risk to Otsuka and Lundbeck?

The main risk is broad generic entry after core compound protection expires. Generic substitution could rapidly reduce price and volume in schizophrenia and MDD, while later-use patents may protect only part of the Alzheimer’s-related revenue.

References

  1. U.S. Food and Drug Administration. (2023). REXULTI (brexpiprazole) prescribing information.
  2. H. Lundbeck A/S. (2024). Annual report 2024.
  3. Otsuka Holdings Co., Ltd. (2024). Integrated report and financial results materials.
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
  5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
  6. Federal Trade Commission. (2024). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.